NeurAxis is no longer asking the market to underwrite a science experiment. The Carmel company spent years selling an ear-worn nerve stimulator through a discounted assistance window; a permanent billing code at the start of this year flipped that mix toward insurers that actually pay list economics. Second-quarter sales more than doubled as children's hospitals billed percutaneous electrical nerve field stimulation as a recognized procedure rather than a courtesy. That is the whole argument in one turn: coverage quality, not gadget novelty, now decides whether this franchise becomes a real pediatric standard or stays a well-documented niche.
Access is still not the same thing as utilization. A mid-September medical policy from a large national insurer lifted the coverage footprint above one hundred twenty million lives, yet the company's own prior-authorization desk is still clearing only about one submission in three. Management continues to warn that substantial doubt exists about the going concern even after cash rebuilt to $8.3 million and funded debt almost disappeared. Operating costs rose faster than sales in the latest quarter because the company hired into coverage it already holds rather than waiting to print a profit. Shareholders are financing a land grab while the conversion engine inside hospitals is only partly built.
Mid-year revenue reached $1.93 million on faster unit growth and a richer selling price, but the operating loss still widened. A July option-for-unit exchange and an attached cash tax bill land against that cash pile in the third quarter. The Veterans Affairs channel and the next national-payer decisions decide whether coverage keeps compounding or whether the multiple is already paying for a conversion that has not arrived. The open question is whether prior-authorization success and hospital program depth catch the coverage map before the at-the-market facility has to reopen.